摘要非酒精性脂肪性肝炎(NASH)慢性化的表现为肝纤维化.肝纤维化程度与远期生存率呈负相关.患者筛选时是否有F2以上的肝纤维化作为纳入NASH进展关注人群重要衡量指标.目前正在进行的NASH药物Ⅲ期临床试验验证受试者均伴有肝纤维化,并且将能否阻止肝纤维化进展作为判断抗NASH药物的主要终点指标.因此,了解NASH肝纤维化的机制,寻找相应干预靶点成为阻止NASH肝纤维化的关键步骤.

abstractsMain indication of nonalcoholic steatohepatitis (NASH) progression is hepatic fibrosis.The extent of fibrosis correlates negatively with long-term comorbidity and survival of NASH patients.Clinical screening for hepatic fibrosis extent higher than F2 is a main criterion for high risk NASH patients.Currently ongoing phase Ⅲ clinical trials for potential pharmacotherapeutics recruit NASH patients with F2-3,and whether tested pharmacotherapeutics block hepatic fibrosis is one of main end-points for assessment of clinical efficacy.Therefore,understanding molecular mechanisms and identifying potential targets are critical for intervention of NASH progression.